Zoetis Q2 Earnings Call Highlights
Zoetis (NYSE:ZTS) reported Q2 declines in dermatology revenue, with global down 16% to $395M and U.S. down 18% to $251M, while the Simparica franchise was flat at $442M. Osteoarthritis pain revenue fell 3% to $147M. Companion diagnostics rose 12% to $118M and livestock rose 11% to $731M. Zoetis cut 2026 guidance to $9.12B-$9.32B revenue and $6.15-$6.25 adjusted EPS.
How this was made
The 30-second read
Why it matters
The key tradable element is the guidance reduction tied to July trends that have not shown stabilization, alongside FX headwinds and continued U.S. pressure in dermatology and parasiticide-related visits. Offsetting positives include livestock growth, diagnostics momentum, and ongoing product expansion expectations (e.g., long-acting Cytopoint approval later in 2026).
Market read
Investors get a fresh, quantified 2026 guidance range and explicit rationale for why stabilization has not yet occurred, which can drive repricing of forward estimates and risk appetite in animal health.
What to watch
The company frames list-price stability and “growth-to-net” investments as volume protection; if promotional effectiveness improves, share losses could slow even without immediate market stabilization.
Background
The piece summarizes Zoetis’ Q2 earnings call, focusing on franchise performance (dermatology, Simparica, OA pain), diagnostics and livestock, and management’s revised 2026 outlook.
Ticker impact
Zoetis cut 2026 revenue and adjusted EPS ranges, citing July sales trends without stabilization, plus FX headwinds and dermatology weakness.
Bias to downside or volatility until investors see evidence of stabilization in dermatology and U.S. parasiticide demand.
The article discloses a concrete guidance reduction with explicit drivers (no stabilization through July, competitive/promotional marketplace, FX headwind) and only partial offsets (livestock growth, diagnostics, ongoing R&D and cost actions).
Market effects
Signals heightened promotional intensity and share pressure in companion-animal dermatology and parasiticides, potentially pressuring peers’ near-term expectations.
U.S. weakness is emphasized (dermatology and Simparica franchise), while international growth and EU/Canada launches provide partial offset.
FX headwind and competitive pricing dynamics are highlighted, which can influence how investors model global revenue durability across animal health.
Counterpoint
Livestock growth is strong and diagnostics adoption plus imaging acquisition expand the platform, so the guidance lower bound may already be conservative and could stabilize faster than implied.
Key entities
- companyZoetis
Animal health company reporting Q2 highlights and revising 2026 revenue and earnings guidance.
- acquisitionVitalRADS
Veterinary teleradiology services platform acquired during the quarter to expand imaging interpretation capabilities.
- productCytopoint (long-acting)
Zoetis expects U.S. approval later in 2026, cited as part of future market expansion.
